Minister of Health Viktor Lyashko stated, that in 2025, inflation for pharmaceutical goods amounted to 13.9%. According to him, the cancellation of marketing payments did not contribute to lowering the price of medicines – on the contrary, the price of certain medicines increased significantly.
“Yes, prices are rising. But this is not unique to the pharmaceutical market. In April 2025, according to the State Statistics Service, inflation for pharmaceutical products was 13.9%. For comparison: electricity rose in price by 63.6%, butter by 30.1%, bread by 21.8%.”, — reported Viktor Lyashko.
The Ministry of Health admits that the new restrictions did not solve the issue of availability of medicines for patients. After the ban on marketing agreements, the average price of medicines that were not included in the “top-100” list of the Ministry of Health increased by 10-20 hryvnias, and some became more expensive by more than 100 hryvnias.
The most noticeable price increase is observed among drugs of foreign production. For example, “Betalok” (AstraZeneca AB, Sweden), which is used for arterial hypertension, has risen in price by an average of 26 hryvnias. “Glucophage XR” (Merck Santé, France) — for 43 hryvnias, “Synjardi” (Boehringer Ingelheim, Germany) — for 103 hryvnias. Even the Ukrainian “Korvityn” from the Borshchagiv chemical and pharmaceutical plant rose in price by 105 hryvnias.
Despite the increase in prices, state control is still focused mainly on pharmacies, while the activities of manufacturers are not regulated. At the same time, it is pharmaceutical companies that form 71.5% of the final price of drugs, while pharmacies influence only 22.6%, and distributors – 5.9%.
